|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide, conjugated to KLH, corresponding to the 2nd extracellular loop of human GRPR.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.7|
|Contains||0.01% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 5 publications below|
OPA1-15619 detects GRPR from human samples.
OPA1-15619 has been successfully used in immunohistochemistry procedures. By immunohistochemistry, OPA1-15619 detects GRPR in formalin fixed, paraffin embedded human tissues.
The OPA1-15619 immunogen is a synthetic peptide, conjugated to KLH, corresponding to the 2nd extracellular loop of human GRPR.
Store at 4°C short term. For longer storage, store at -20°C, Avoiding freeze/thaw cycles.
Gastrin-Releasing Peptide Receptor (GRPR) has been reported in brain, breast, colon, lung, lymph node, ovary, placenta, prostate, stomach, and uterus. It has also been shown to be expressed in several cancers, including those in breast, colon, lung, ovary, pancreas, and prostate.
G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Gastrin-releasing peptide receptor expression in lung cancer.
OPA1-15619 was used in immunohistochemistry to study the expression of GRPR in small cell and non-small cell lung cancer
|Mattei J,Achcar RD,Cano CH,Macedo BR,Meurer L,Batlle BS,Groshong SD,Kulczynski JM,Roesler R,Dal Lago L,Brunetto AT,Schwartsmann G||Archives of pathology and laboratory medicine (138:98)||2014|
BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer.
OPA1-15619 was used in immunohistochemistry to investigate the involvement of BDNF in colorectal cancer resistance to GRPR treatment
|Brunetto de Farias C,Rosemberg DB,Heinen TE,Koehler-Santos P,Abujamra AL,Kapczinski F,Brunetto AL,Ashton-Prolla P,Meurer L,Reis Bogo M,Damin DC,Schwartsmann G,Roesler R||Oncology (79:430)||2011|
BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells.
OPA1-15619 was used in immunohistochemistry to investigate the influence of BDNF and PDE4 on medulloblastoma cell survival
|Schmidt AL,de Farias CB,Abujamra AL,Kapczinski F,Schwartsmann G,Brunetto AL,Roesler R||Journal of molecular neuroscience : MN (40:303)||2010|
Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling.
OPA1-15619 was used in immunohistochemistry to study the effect of gastrin-releasing peptide on U138-MG glioblastoma cell proliferation and its mechanism
|Farias CB,Lima RC,Lima LO,Flores DG,Meurer L,Brunetto AL,Schwartsmann G,Roesler R||Oncology (75:27)||2008|
Gastrin-releasing peptide receptors regulate proliferation of C6 Glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism.
OPA1-15619 was used in immunohistochemistry to investigate the mechanism of glima cell proliferation mediated by gastrin-releasing peptide receptors
|Flores DG,de Farias CB,Leites J,de Oliveira MS,Lima RC,Tamajusuku AS,Di Leone LP,Meurer L,Brunetto AL,Schwartsmann G,Lenz G,Roesler R||Current neurovascular research (5:99)||2008|